Fort Myers,
Florida
33901
Purpose:
The primary objective of the study is to determine the efficacy of thalidomide for the
treatment of anemia in patients with myelodysplastic syndromes (MDS).
Criteria:
- Eligible patients must have a diagnosis of myelodysplastic syndrome
- Life expectancy of at least 6 months.
- Patients must be able to adhere to the study visit schedule and other protocol
requirements.
- Patients must understand and voluntarily sign an informed consent document.
- Women of childbearing potential (WCBP) must agree to practice abstinence or to use
TWO methods of contraception beginning 4 weeks prior to the start of study medication
and throughout the course of treatment.
- Males must use barrier contraception when engaging in reproductive sexual activity
with women of childbearing potential.